This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.Here is a sample of this item:Dynavax Appoints Francis R. Cano, Ph.D. to Board of Directors 2009-11-05 06:45 ET - News Release
BERKELEY, Calif. -- (Business Wire)
Dynavax Technologies Corporation (Nasdaq:DVAX) announced today that
Francis R. Cano, Ph.D. has been appointed to Dynavax’s Board of
Directors effective November 3, 2009.
“A recognized scientific leader in vaccines and infectious diseases,
Francis brings unique expertise and broad experience in research,
development, and commercialization to Dynavax,” commented Arnold L.
Oronsky, Ph.D., Chairman of the Board of Directors of Dynavax. “Francis
will provide valuable perspective as Dynavax advances its plans for its
Phase 3 hepatitis B vaccine and pipeline products.”
Dr. Cano is President and Founder of Cano Biotech Corp., a consulting
firm focusing on the vaccine business. Previously, Dr. Cano was
President and Chief Operating Officer for Aviron, which was later
acquired by MedImmune in 2001. As a Co-Founder of Aviron, he completed
two rounds of venture financing, a licensing agreement with SmithKline
Biologicals, and in-licensed Flu-Mist influenza vaccine from the
National Institutes of Health. For 21 years, Dr. Cano worked with the
Lederle Laboratories Division of American Cyanamid, most recently as
Vice President and General Manager of the Biologicals unit.
The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try,
click here for a free 30 day trial subscription. |
Top
Print this Page